Advertisement

Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion

Published:November 16, 2022DOI:https://doi.org/10.1016/j.thromres.2022.11.009

      Abstract

      Background

      A significant proportion of patients with retinal vein occlusion (RVO) are antiphospholipid antibodies (aPL) carriers. Relapsing disease occurs in nearly 10 % of cases and the role of aPL has not been established. The adjusted global antiphospholipid syndrome score (aGAPSS) was developed to assess the risk of clinical events in aPL carriers and its role in the management of RVO patients is unknown.

      Objective

      To analyze the values of aGAPSS in a large cohort of patients with RVO and population-based controls, and to assess its usefulness to predict RVO relapses.

      Methods

      Case-control study of RVO patients and population-based controls of similar age and sex. We have assessed and compared the aPL profile and the aGAPSS score in patients with and without relapsing disease and controls.

      Results

      Four-hundred and seventy-two RVO patients and 346 controls were included. Fifty-seven RVO patients had antiphospholipid syndrome (RVO-APS). Of them, 75.4 % had a high-risk profile compared to 3 % in controls (p = 0.0001). The median aGAPSS values were 8 [7–13], 3 [1–4], and 3 [0–4], in RVO-APS, RVO no-APS, and controls. Nineteen patients had had a recurrence of RVO before inclusion and 8 during the follow-up. APS was more prevalent in relapsing patients. In the adjusted multivariable regression model, the best predictor for RVO recurrence during the follow-up was an aGAPSS score ≥6 (OR 5.5, CI95% 1.3–23.7; p = 0.023).

      Conclusions

      In patients with RVO, once the control of vascular risk factors has been optimized, the aGAPSS might help to identify those at risk of relapsing disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Napal J.J.
        • Sedano C.
        • Cañal J.
        • Hernández J.L.
        Thrombophilia and vascular risk factors in retinal vein occlusion.
        Rev. Clin. Esp. (Barc.). 2013; 213: 229-234https://doi.org/10.1016/j.rce.2013.01.012
        • Werther W.
        • Chu L.
        • Holekamp N.
        • Do D.V.
        • Rubio R.G.
        Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion.
        Arch. Ophthalmol. 2011; 129: 326-331https://doi.org/10.1001/archophthalmol.2011.2
        • Cugati S.
        • Wang J.J.
        • Knudtson M.D.
        • et al.
        Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts.
        Ophthalmology. 2007; 114: 520-524https://doi.org/10.1016/j.ophtha.2006.06.061
        • Janssen M.C.
        • Den M.
        • Cruysberg J.R.
        • Wollersheim H.
        • Bredie S.J.
        Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors.
        Thromb. Haemost. 2005; 93: 1021-1026https://doi.org/10.1160/TH04-11-0768
        • Napal J.J.
        • Neila S.
        • Pérez-Montes R.
        • Sierra I.
        • Ruiz S.
        • Hernández J.L.
        The role of coagulation disorders in patients with retinal vein occlusion.
        QJM. 2016; 109: 97-102https://doi.org/10.1093/qjmed/hcv088
        • Hernández J.L.
        • Sanlés I.
        • Pérez-Montes R.
        • et al.
        Antiphospholipid syndrome and antiphospholipid antibody profile in patients with retinal vein occlusion.
        Thromb. Res. 2020; 190: 63-68
        • Di-Capua M.
        • Coppola A.
        • Albisinni R.
        • et al.
        Cardiovascular risk factors and outcome in patients with retinal vein occlusion.
        J. Thromb. Thrombolysis. 2010; 30: 16-22https://doi.org/10.1016/j.thromres.2020.04.005
        • Sodi A.
        • Giambene B.
        • Marcucci R.
        • et al.
        Atherosclerotic and thrombophilic risk factors in patients with recurrent central retinal vein occlusion.
        Eur. J. Ophthalmol. 2008; 18: 233-238https://doi.org/10.1177/112067210801800211
        • Dodson P.M.
        • Kubicki A.J.
        • Taylor K.G.
        • Kritzinger E.E.
        Medical conditions underlying recurrence of retinal vein occlusion.
        Br. J. Ophthalmol. 1985; 69: 493-496https://doi.org/10.1136/bjo.69.7.493
        • Radin M.
        • Sciascia S.
        • Erkan D.
        • APS ACTION.
        • et al.
        The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort.
        Semin. Arthritis. Rheum. 2019; 49: 464-468https://doi.org/10.1016/j.semarthrit.2019.04.009
        • Sciascia S.
        • Sanna G.
        • Murru V.
        • Roccatell D.
        • Khamashta M.A.
        • Bertolaccini M.L.
        GAPSS: the global anti-phospholipid syndrome score.
        Rheumatology (Oxford). 2013; 52: 1397-1403https://doi.org/10.1093/rheumatology/kes388
        • Del Barrio-Longarela S.
        • Martínez-Taboada V.M.
        • Blanco-Olavarri P.
        • et al.
        Does adjusted global antiphospholipid syndrome score (aGAPSS) predict the obstetric outcome in antiphospholipid antibody carriers? A single-center study.
        Clin. Rev. Allergy Immunol. 2021; 15https://doi.org/10.1007/s12016-021-08915-9
        • Fernandez N.
        • Saez L.
        • Salvador C.
        • Calvo J.M.
        • Velilla J.
        Independent validation of the adjusted GAPSS: role of thrombotic risk assessment in the real-life setting.
        Lupus. 2017; 26: 1328-1332https://doi.org/10.1177/0961203317703493
        • Radin M.
        • Schreiber K.
        • Costanzo P.
        • et al.
        The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction.
        Int. J. Cardiol. 2017; 240: 72-77https://doi.org/10.1016/j.ijcard.2017.02.155
        • Hernández J.L.
        • Olmos J.M.
        • Romaña G.
        • et al.
        Influence of vitamin D status on the effect of statins on bone mineral density and bone turnover markers in postmenopausal women.
        J. Clin. Endocrinol. Metab. 2014; 99: 3304-3309https://doi.org/10.1210/jc.2014-1102
        • Hernández J.L.
        • Olmos J.M.
        • Pariente E.
        • et al.
        Metabolic syndrome and bone metabolism: the Camargo cohort study.
        Menopause. 2010; 17: 955-961https://doi.org/10.1097/gme.0b013e3181e39a15
        • Miyakis S.
        • Lockshin M.D.
        • Atsumi T.
        • et al.
        International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
        J. Thromb. Haemost. 2006; : 295-306https://doi.org/10.1111/j.1538-7836.2006.01753.x
        • Paciullo F.
        • Valeriani E.
        • Porfidia M. A.
        • et al.
        Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET).
        Blood Transfus. 2022; 20: 341-347https://doi.org/10.2450/2022.0276-21
        • American Diabetes Association
        2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021.
        Diabetes Care. 2021; 44: S15-S33https://doi.org/10.2337/dc21-S002
        • Tektonidou M.G.
        • Andreoli L.
        • Limper M.
        • et al.
        EULAR recommendations for the management of antiphospholipid syndrome in adults.
        Ann. Rheum. Dis. 2019; 78: 1296-1304https://doi.org/10.1136/annrheumdis-2019-215213
        • Pengo V.
        • Tripodi A.
        • Reber G.
        • et al.
        Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.
        J. Thromb. Haemost. 2009; 7: 1737-1740https://doi.org/10.1111/j.1538-7836.2009.03555.x
        • Di Minno M.N.D.
        • Scalera A.
        • Tufano A.
        • et al.
        The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies.
        Atherosclerosis. 2018; 278: 60-65https://doi.org/10.1016/j.atherosclerosis.2018.09.010
        • Otomo K.
        • Atsumi T.
        • Amengual O.
        • et al.
        Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events.
        Arthritis Rheum. 2012; 64: 504-512https://doi.org/10.1002/art.33340
        • Oku K.
        • Amengual O.
        • Yasuda S S.
        How to identify high-risk APS patients: clinical utility and predictive values of validated scores.
        Curr. Rheumatol. Rep. 2017; 19: 51https://doi.org/10.1007/s11926-017-0674-4